A 64-year-old woman is hospitalized for a massive unprovoked pulmonary embolism. She is in… — USMLE Step 3

A 64-year-old woman is hospitalized for a massive unprovoked pulmonary embolism. She is initially managed with a continuous intravenous unfractionated heparin infusion. Six days after admission, routine laboratory monitoring reveals a platelet count of $115,000/\mu L$ , a significant decline from her admission baseline of $280,000/\mu L$ . Concurrently, she reports new-onset right calf pain, and Doppler ultrasonography confirms a new right lower extremity deep venous thrombosis.

Heparin-induced thrombocytopenia (HIT) is suspected. Heparin is immediately discontinued, and a continuous intravenous infusion of argatroban is started. A serotonin release assay subsequently returns positive, confirming the diagnosis of HIT.

Over the next 72 hours, the patient's platelet count steadily recovers to $190,000/\mu L$ . The care team decides to transition her to oral warfarin for long-term anticoagulation. Warfarin is initiated at $5 \text{ mg}$ daily while the argatroban infusion is maintained.

Today is the fourth day of combined argatroban and warfarin therapy. The patient is hemodynamically stable without any signs of clinical bleeding. Morning laboratory studies reveal the following:

* Platelet count: $230,000/\mu L$
* Activated partial thromboplastin time (aPTT): $62 \text{ seconds}$ (target therapeutic range: $45$ - $75 \text{ seconds}$ )
* Prothrombin time (PT): $36 \text{ seconds}$
* International Normalized Ratio (INR): $3.1$

Which of the following is the most appropriate next step in the monitoring and treatment evaluation of this patient's anticoagulation?

Continue argatroban and warfarin, and recheck the INR the following dayAnswer
B
Discontinue argatroban, continue warfarin, and recheck the INR in 4 to 6 hours
C
Decrease the argatroban infusion rate to lower the aPTT, then reassess the INR
D
Discontinue warfarin, continue argatroban, and administer oral vitamin K
E
Discontinue argatroban, continue warfarin, and initiate therapeutic subcutaneous enoxaparin

Answer

Continue argatroban and warfarin, and recheck the INR the following day.

The correct approach recognizes the critical drug-assay interaction between argatroban and the prothrombin time (PT). Argatroban is a direct thrombin inhibitor that artificially prolongs the measured PT and INR. When bridging a patient from argatroban to warfarin, the measured INR reflects the combined effects of both medications. To ensure that the patient is adequately anticoagulated with warfarin alone before removing the parenteral bridge, standard transition protocols require maintaining combined therapy until the co-therapy INR exceeds 4.0 (for patients receiving up to

2 \mu\text{g/kg/min}

of argatroban). Once the INR is > 4.0, argatroban is stopped, and the INR is repeated 4 to 6 hours later to ascertain the true warfarin-induced INR, which must be within the therapeutic range of 2.0 to 3.0. In this clinical scenario, the co-therapy INR is only 3.1. Consequently, the true, underlying warfarin-induced INR is subtherapeutic. Continuing both medications and rechecking the laboratory parameters the following day is the only safe and appropriate next step.

Step-by-Step Solution

Analyze the patient's clinical situation and current medications.

The patient has confirmed HIT and is on day 4 of bridging therapy from intravenous argatroban to oral warfarin.

Establishing the specific pharmacological context is necessary because different anticoagulants have unique bridging protocols and assay interactions.

Interpret the laboratory findings in the context of the specific drug interactions.

The measured INR is 3.1. Argatroban directly inhibits thrombin and artificially prolongs the PT and INR. Therefore, the measured INR represents the combined effect of both argatroban and warfarin.

Failure to recognize the drug-assay interaction would lead to a false assumption that the patient's warfarin therapy is already therapeutic.

Apply the standard protocol for transitioning from argatroban to warfarin.

Guidelines dictate that argatroban should only be discontinued when the co-therapy INR is strictly greater than 4.0. Because the INR is currently 3.1, the true, isolated warfarin INR is reliably subtherapeutic.

Stopping the parenteral bridge prematurely puts the patient at high risk for catastrophic recurrent thrombosis, especially with active HIT.

Determine the best next step in management.

The correct action is to continue both medications and monitor the INR daily until it exceeds the > 4.0 threshold.

This safely extends the bridging period until adequate vitamin K antagonism is definitively achieved.

Key Concept

During the transition from argatroban to warfarin in patients with Heparin-Induced Thrombocytopenia (HIT), argatroban artificially elevates the PT/INR. Argatroban should not be discontinued until the co-therapy INR is > 4.0, after which the INR is rechecked in 4-6 hours to confirm a true therapeutic warfarin level (INR 2.0-3.0).

Estimated Time:2m 0s

Question

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Topics

More questions from this topic